Enveric Biosciences Inc Financials
This page shows Enveric Biosciences Inc (ENVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Enveric’s reported profits mask a cash-burning development model still financed mainly through external capital raises.
Across FY2023-FY2025, net income stayed positive while operating cash flow stayed negative, ending the latest year at$12.1M versus-$8.1M . Paired with continuing operating losses, that mismatch indicates the reported profit is being created by non-operating accounting items rather than by a business that funds itself.
The balance sheet improved, with year-end cash at
The cost base is being compressed rather than absorbed by sales, with operating loss narrowed to
Financial Health Signals
Enveric Biosciences Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Enveric Biosciences Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
For every $1 of reported earnings, Enveric Biosciences Inc used $0.67 of operating cash (-$8.1M OCF vs $12.1M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Enveric Biosciences Inc reported an operating loss of $8.8M against $106 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Enveric Biosciences Inc's EBITDA was -$8.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.8% from the prior year.
Enveric Biosciences Inc reported $12.1M in net income in fiscal year 2025. This represents an increase of 26.0% from the prior year.
Enveric Biosciences Inc earned -$36.24 per diluted share (EPS) in fiscal year 2025. This represents an increase of 84.1% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Enveric Biosciences Inc held $4.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Enveric Biosciences Inc's ROE was 289.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 313.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Enveric Biosciences Inc invested $2.8M in research and development in fiscal year 2025. This represents a decrease of 2.1% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ENVB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY15 | FY14 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $43.0M-11.5% | $48.6M+34.4% | $36.1M+78.4% | $20.3M | $16.8M+173.5% | $6.1M | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $34.0M-11.3% | $38.4M+31.3% | $29.2M+118.2% | $13.4M | $15.1M+188.8% | $5.2M | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $9.0M-12.3% | $10.2M+47.8% | $6.9M+0.9% | $6.9M | $1.7M+85.5% | $911K | N/A | N/A |
| R&D Expenses | N/A | $2.8M-2.1% | $2.8M-60.8% | $7.3M-9.7% | $8.0M+67.6% | $4.8M+2650.9% | $174K | N/A | N/A | N/A | $55K | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | $5.8M-10.2% | $6.5M-27.1% | $8.9M-23.7% | $11.6M-43.4% | $20.5M+285.1% | $5.3M | N/A | $10.8M-41.7% | $18.5M+97.7% | $9.4M+63.6% | $5.7M | -$33K-20.6% | -$27K | $23K-27.7% | $31K |
| Operating Income | N/A | -$8.8M+8.9% | -$9.6M+41.4% | -$16.4M+40.0% | -$27.4M+57.6% | -$64.6M-1050.4% | -$5.6M | N/A | -$7.1M+34.4% | -$10.9M-102.5% | -$5.4M-577.6% | -$794K | $33K+20.6% | $27K | -$23K+27.7% | -$31K |
| Interest Expense | N/A | -$106-148.4% | $219-94.1% | $4K-29.4% | $5K-49.1% | $10K-97.7% | $445K+444.2% | $82K-88.8% | $730K+26.9% | $575K-23.4% | $751K+215.0% | $238K | N/A | $15 | N/A | N/A |
| Income Tax | N/A | N/A | $9K-69.1% | $29K+101.9% | -$1.5M+80.1% | -$7.5M | N/A | $389K-93.9% | $6.3M+365.4% | -$2.4M+36.2% | -$3.7M-2817.5% | -$128K | $833-42.6% | $1K | $2K-2.7% | $2K |
| Net Income | N/A | $12.1M+26.0% | $9.6M-45.1% | $17.5M+194.7% | -$18.5M+62.3% | -$49.0M-613.5% | -$6.9M | N/A | -$16.9M-86.2% | -$9.1M-226.4% | -$2.8M-241.6% | -$814K | -$34K-20796.9% | -$161 | -$25K+26.2% | -$33K |
| EPS (Diluted) | — | -$36.24+84.1% | -$228.48 | -$121.29 | -$13.00 | N/A | N/A | -$2.83 | -$20.47 | -$0.75-257.1% | -$0.21-200.0% | -$0.07 | $4.27-32.5% | $6.33 | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
No annual filing on record for: FY2013.
ENVB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY15 | FY14 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.1M+65.3% | $3.1M-28.3% | $4.3M-78.0% | $19.6M-26.8% | $26.7M+552.2% | $4.1M+3665.9% | $109K-99.6% | $29.6M-43.2% | $52.2M+32.1% | $39.5M+185.6% | $13.8M | $4.5M+29.7% | $3.4M | $6K-75.1% | $22K |
| Current Assets | $4.9M+80.5% | $2.7M-23.6% | $3.6M-80.6% | $18.4M+3.9% | $17.7M+678.2% | $2.3M+1995.0% | $109K-98.9% | $10.1M-31.3% | $14.6M+45.5% | $10.1M+40.2% | $7.2M | $4.3M+26.0% | $3.4M | $6K-75.1% | $22K |
| Cash & Equivalents | $4.7M+108.7% | $2.2M-2.1% | $2.3M-87.1% | $17.7M+2.1% | $17.4M+999.6% | $1.6M | N/A | $1.4M-71.9% | $4.9M+253.8% | $1.4M-26.5% | $1.9M | $826K+120.3% | $375K | $1K-92.4% | $18K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $7.9M-10.9% | $8.8M+9.7% | $8.1M+65.4% | $4.9M | $3.0M+1.5% | $2.9M | N/A | N/A |
| Goodwill | N/A | N/A | N/A | $380K-76.1% | $1.6M | N/A | N/A | $13.7M-37.3% | $21.9M+28.1% | $17.1M+392.4% | $3.5M | N/A | N/A | N/A | N/A |
| Total Liabilities | $918K-38.4% | $1.5M-36.4% | $2.3M-41.4% | $4.0M-9.5% | $4.4M+547.8% | $681K-64.5% | $1.9M-93.5% | $29.7M-9.3% | $32.7M+17.6% | $27.8M+105.1% | $13.6M | $3.5M+15.7% | $3.0M | $26K+43.4% | $18K |
| Current Liabilities | $918K-38.4% | $1.5M-36.4% | $2.3M-41.4% | $4.0M+46.0% | $2.7M+301.8% | $681K | N/A | $14.7M-51.6% | $30.4M+138.9% | $12.7M+48.2% | $8.6M | $3.5M+15.7% | $3.0M | $26K+43.4% | $18K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | $740K | $0-100.0% | $1.1M-26.4% | $1.5M-69.3% | $5.0M | N/A | N/A | N/A | N/A |
| Total Equity | $4.2M+162.3% | $1.6M-18.6% | $2.0M-86.7% | $14.7M-34.2% | $22.3M+553.1% | $3.4M+288.5% | -$1.8M-2667.7% | -$65K-100.3% | $19.4M+66.7% | $11.7M+4411.5% | $259K | $973K+129.1% | $425K | -$20K-540.5% | $5K |
| Retained Earnings | -$114.8M-8.3% | -$106.1M-9.9% | -$96.5M-21.8% | -$79.2M-30.4% | -$60.7M-416.5% | -$11.8M-140.2% | -$4.9M+85.8% | -$34.5M-129.9% | -$15.0M-291.2% | -$3.8M-264.1% | -$1.1M | $838K+102.1% | $415K | -$47.4M-0.1% | -$47.4M |
Not reported in any period shown, so not listed: Inventory.
No annual filing on record for: FY2013.
ENVB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY15 | FY14 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.6M | -$8.1M-5.4% | -$7.7M+45.2% | -$14.1M+17.8% | -$17.1M-49.7% | -$11.5M-194.6% | -$3.9M | N/A | -$2.6M+6.4% | -$2.7M-1.4% | -$2.7M+30.7% | -$3.9M | -$43K-99.5% | -$22K | -$25K+18.1% | -$30K |
| Capital Expenditures | N/A | N/A | N/A | $5K-99.1% | $584K+207.9% | $190K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | -$14.1M+20.5% | -$17.7M-52.2% | -$11.6M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | $12K+102.0% | -$584K-126.7% | $2.2M+5062.5% | -$44K+84.5% | -$284K+92.2% | -$3.6M-2042.5% | -$170K+97.4% | -$6.6M-259.0% | -$1.8M | -$500K-15531.1% | -$3K | N/A | N/A |
| Financing Cash Flow | $14.0M | $10.6M+37.9% | $7.7M+671.3% | -$1.3M-107.4% | $18.2M-27.0% | $24.9M+350.2% | $5.5M | N/A | $2.7M-58.0% | $6.4M-27.1% | $8.8M+41.1% | $6.2M | $48K+134.1% | $21K | $8K-83.1% | $47K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
No annual filing on record for: FY2013.
ENVB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY15 | FY14 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 20.9%-0.2pp | 21.1%+1.9pp | 19.2%-14.7pp | 33.9% | 10.1%-4.8pp | 14.8% | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -16.6%+5.8pp | -22.4%-7.5pp | -14.9%-11.0pp | -3.9% | 0.2%-0.2pp | 0.4% | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -39.3%-20.6pp | -18.7%-11.0pp | -7.7%-3.7pp | -4.0% | -0.2%-0.2pp | 0.0% | N/A | N/A |
| Return on Equity | 289.6%-313.1pp | 602.7%-291.8pp | 894.5%+1020.4pp | -125.9%+93.7pp | -219.6%-18.6pp | -201.0% | N/A | N/A | -46.7%-22.8pp | -23.8%+291.0pp | -314.9% | -3.5%-3.4pp | 0.0% | N/A | -732.8% |
| Return on Assets | 237.4%-74.0pp | 311.4%-95.6pp | 407.0%+501.5pp | -94.5%+88.8pp | -183.3%-15.7pp | -167.6% | N/A | -57.0%-39.6pp | -17.4%-10.3pp | -7.0%-1.2pp | -5.9% | -0.8%-0.8pp | 0.0% | -439.7%-291.0pp | -148.7% |
| Current Ratio | 5.38+3.5x | 1.84+0.3x | 1.53-3.1x | 4.61-1.9x | 6.48+3.1x | 3.35 | N/A | 0.69+0.2x | 0.48-0.3x | 0.790.0x | 0.84 | 1.24+0.1x | 1.14 | 0.22-1.0x | 1.25 |
| Debt-to-Equity | 0.22-0.7x | 0.94-0.3x | 1.20+0.9x | 0.27+0.1x | 0.200.0x | 0.20 | N/A | N/A | 0.06-0.1x | 0.13-19.2x | 19.34 | 3.59-3.5x | 7.10 | N/A | 3.93 |
Not reported in any period shown, so not listed: FCF Margin.
No annual filing on record for: FY2013.
Similar Companies
Where Enveric Biosciences Inc Ranks
Frequently Asked Questions
Is Enveric Biosciences Inc profitable?
Yes, Enveric Biosciences Inc (ENVB) reported a net income of $12.1M in fiscal year 2025.
What is Enveric Biosciences Inc's EBITDA?
Enveric Biosciences Inc (ENVB) had EBITDA of -$8.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Enveric Biosciences Inc's return on equity (ROE)?
Enveric Biosciences Inc (ENVB) has a return on equity of 289.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Enveric Biosciences Inc's operating cash flow?
Enveric Biosciences Inc (ENVB) recorded an outflow of $8.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Enveric Biosciences Inc's total assets?
Enveric Biosciences Inc (ENVB) had $5.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Enveric Biosciences Inc spend on research and development?
Enveric Biosciences Inc (ENVB) invested $2.8M in research and development during fiscal year 2025.
What is Enveric Biosciences Inc's current ratio?
Enveric Biosciences Inc (ENVB) had a current ratio of 5.38 as of fiscal year 2025, which is generally considered healthy.
What is Enveric Biosciences Inc's debt-to-equity ratio?
Enveric Biosciences Inc (ENVB) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Enveric Biosciences Inc's return on assets (ROA)?
Enveric Biosciences Inc (ENVB) had a return on assets of 237.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Enveric Biosciences Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Enveric Biosciences Inc (ENVB) held $4.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.1M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Enveric Biosciences Inc's Piotroski F-Score?
Enveric Biosciences Inc (ENVB) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Enveric Biosciences Inc's earnings high quality?
For every $1 of reported earnings, Enveric Biosciences Inc (ENVB) used $0.67 of operating cash (-$8.1M OCF vs $12.1M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Enveric Biosciences Inc cover its interest payments?
Enveric Biosciences Inc (ENVB) reported an operating loss of $8.8M against $106 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.